Two patients with familial hypercholesterolemia who were successfully weaned from low-density lipoprotein apheresis after treatment with evolocumab

Akihito Tanaka, Daijo Inaguma, Yu Watanabe, Eri Ito, Naoki Kamegai, Hiroya Shimogushi, Hibiki Shinjo, Kiyomi Koike, Yasuhiro Otsuka, Asami Takeda

Research output: Contribution to journalArticle

Abstract

Two elderly patients (a 76-year-old man and a 75-year-old woman), who had been previously diagnosed with familial hypercholesterolemia (at 58 and 48 years of age, respectively) underwent long-term treatment with oral therapy and low-density lipoprotein (LDL) apheresis. As their LDL cholesterol levels remained high (>150 mg/dL and >120 mg/dL, respectively) and their familial hypercholesterolemia was complicated with angina pectoris, we added evolocumab to their prescription. Thereafter, their LDL cholesterol levels decreased rapidly, and the patients were successfully weaned from LDL apheresis. Evolocumab therapy should thus be considered when LDL apheresis cannot achieve the target LDL cholesterol levels, though the prognosis of such treatment remains unclear.

Original languageEnglish
Pages (from-to)1531-1535
Number of pages5
JournalInternal Medicine
Volume56
Issue number12
DOIs
Publication statusPublished - 01-01-2017

Fingerprint

Hyperlipoproteinemia Type II
Blood Component Removal
LDL Lipoproteins
LDL Cholesterol
Angina Pectoris
Therapeutics
Prescriptions
AMG 145

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Tanaka, Akihito ; Inaguma, Daijo ; Watanabe, Yu ; Ito, Eri ; Kamegai, Naoki ; Shimogushi, Hiroya ; Shinjo, Hibiki ; Koike, Kiyomi ; Otsuka, Yasuhiro ; Takeda, Asami. / Two patients with familial hypercholesterolemia who were successfully weaned from low-density lipoprotein apheresis after treatment with evolocumab. In: Internal Medicine. 2017 ; Vol. 56, No. 12. pp. 1531-1535.
@article{21cb53feb11840339ee6e57b0b8f23b9,
title = "Two patients with familial hypercholesterolemia who were successfully weaned from low-density lipoprotein apheresis after treatment with evolocumab",
abstract = "Two elderly patients (a 76-year-old man and a 75-year-old woman), who had been previously diagnosed with familial hypercholesterolemia (at 58 and 48 years of age, respectively) underwent long-term treatment with oral therapy and low-density lipoprotein (LDL) apheresis. As their LDL cholesterol levels remained high (>150 mg/dL and >120 mg/dL, respectively) and their familial hypercholesterolemia was complicated with angina pectoris, we added evolocumab to their prescription. Thereafter, their LDL cholesterol levels decreased rapidly, and the patients were successfully weaned from LDL apheresis. Evolocumab therapy should thus be considered when LDL apheresis cannot achieve the target LDL cholesterol levels, though the prognosis of such treatment remains unclear.",
author = "Akihito Tanaka and Daijo Inaguma and Yu Watanabe and Eri Ito and Naoki Kamegai and Hiroya Shimogushi and Hibiki Shinjo and Kiyomi Koike and Yasuhiro Otsuka and Asami Takeda",
year = "2017",
month = "1",
day = "1",
doi = "10.2169/internalmedicine.56.7958",
language = "English",
volume = "56",
pages = "1531--1535",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "12",

}

Two patients with familial hypercholesterolemia who were successfully weaned from low-density lipoprotein apheresis after treatment with evolocumab. / Tanaka, Akihito; Inaguma, Daijo; Watanabe, Yu; Ito, Eri; Kamegai, Naoki; Shimogushi, Hiroya; Shinjo, Hibiki; Koike, Kiyomi; Otsuka, Yasuhiro; Takeda, Asami.

In: Internal Medicine, Vol. 56, No. 12, 01.01.2017, p. 1531-1535.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Two patients with familial hypercholesterolemia who were successfully weaned from low-density lipoprotein apheresis after treatment with evolocumab

AU - Tanaka, Akihito

AU - Inaguma, Daijo

AU - Watanabe, Yu

AU - Ito, Eri

AU - Kamegai, Naoki

AU - Shimogushi, Hiroya

AU - Shinjo, Hibiki

AU - Koike, Kiyomi

AU - Otsuka, Yasuhiro

AU - Takeda, Asami

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Two elderly patients (a 76-year-old man and a 75-year-old woman), who had been previously diagnosed with familial hypercholesterolemia (at 58 and 48 years of age, respectively) underwent long-term treatment with oral therapy and low-density lipoprotein (LDL) apheresis. As their LDL cholesterol levels remained high (>150 mg/dL and >120 mg/dL, respectively) and their familial hypercholesterolemia was complicated with angina pectoris, we added evolocumab to their prescription. Thereafter, their LDL cholesterol levels decreased rapidly, and the patients were successfully weaned from LDL apheresis. Evolocumab therapy should thus be considered when LDL apheresis cannot achieve the target LDL cholesterol levels, though the prognosis of such treatment remains unclear.

AB - Two elderly patients (a 76-year-old man and a 75-year-old woman), who had been previously diagnosed with familial hypercholesterolemia (at 58 and 48 years of age, respectively) underwent long-term treatment with oral therapy and low-density lipoprotein (LDL) apheresis. As their LDL cholesterol levels remained high (>150 mg/dL and >120 mg/dL, respectively) and their familial hypercholesterolemia was complicated with angina pectoris, we added evolocumab to their prescription. Thereafter, their LDL cholesterol levels decreased rapidly, and the patients were successfully weaned from LDL apheresis. Evolocumab therapy should thus be considered when LDL apheresis cannot achieve the target LDL cholesterol levels, though the prognosis of such treatment remains unclear.

UR - http://www.scopus.com/inward/record.url?scp=85020488977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020488977&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.56.7958

DO - 10.2169/internalmedicine.56.7958

M3 - Article

VL - 56

SP - 1531

EP - 1535

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 12

ER -